17. Convertible Loan
(thousands of €) |
2025 |
|---|---|
Cost at January 1 |
– |
Issuance of convertible loan facility |
20,000 |
Cost at December 31 |
20,000 |
|
|
Fair value adjustment at January 1 |
– |
Fair value adjustment of the year |
1,175 |
Fair value adjustment at December 31 |
1,175 |
Net book value at December 31 |
21,175 |
In April 2025, we and Onco3R Therapeutics (Onco3R) signed an agreement under which multiple small molecule immunology and oncology assets have been sold to Onco3R. Under the terms of the agreement, we participated in Onco3R’s start-up capital via a convertible loan facility with a nominal amount of €20 million, with 8% interest per annum receivable at maturity date, which is the earlier of conversion and five years after issue date. At conversion, the convertible loan would convert in the most senior class of preferred equity shares of Onco3R at the time of the completion of a future equity financing round by Onco3R in which third party investors subscribe for new Onco3R shares of at least €20 million.
This convertible loan facility is measured at fair value through profit or loss. As per December 31, 2025, the only fair value change recognized is related to the capitalized interest.